Opinion|Videos|March 21, 2024
Initial Results from Phase 2 COBRA Study in Colorectal Cancer
Stacey Cohen, MD, reviews the initial results from the phase 2 COBRA study focused on ctDNA as a predictive biomarker in adjuvant chemotherapy for patients with stage II colon cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
2
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
3
CARTITUDE-2 Cohort A Follow-Up Data and Preparing Patients for CAR TCell Therapy
4
Ciltacabtagene Autoleucel Manufacturing, Debulking, and Bridging in Multiple Myeloma
5